Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 352

1.

Clinical and Angiographic Outcomes With a Novel Radiopaque Sirolimus-Eluting Bioresorbable Vascular Scaffold.

Chevalier B, Abizaid A, Carrié D, Frey N, Lutz M, Weber-Albers J, Dudek D, Weng SC, Akodad M, Anderson J, Stone GW.

Circ Cardiovasc Interv. 2019 Jun;12(6):e007283. doi: 10.1161/CIRCINTERVENTIONS.118.007283. Epub 2019 Jun 10.

PMID:
31177821
2.

Absorb bioresorbable scaffold versus Xience metallic stent for prevention of restenosis following percutaneous coronary intervention in patients at high risk of restenosis: Rationale and design of the COMPARE ABSORB trial.

Chang CC, Onuma Y, Achenbach S, Barbato E, Chevalier B, Cook S, Dudek D, Escaned J, Gori T, Kočka V, Tarantini G, West NEJ, Morice MC, Tijssen JGP, van Geuns RJ, Smits PC; COMPARE ABSORB trial investigators.

Cardiovasc Revasc Med. 2019 Apr 16. pii: S1553-8389(19)30239-8. doi: 10.1016/j.carrev.2019.04.013. [Epub ahead of print]

PMID:
31153846
3.

TAVR for Failed Surgical Aortic Bioprostheses Using a Self-Expanding Device: 1-Year Results From the Prospective VIVA Postmarket Study.

Tchétché D, Chevalier B, Holzhey D, Harnath A, Schäfer U, Teiger E, Manigold T, Modine T, Souteyrand G, Champagnac D, Oh JK, Li S, Verhoye JP, Kornowski R; VIVA Investigators.

JACC Cardiovasc Interv. 2019 May 27;12(10):923-932. doi: 10.1016/j.jcin.2019.02.029.

PMID:
31122349
4.

Hemodynamic Performances and Clinical Outcomes in Patients Undergoing Valve-in-Valve Versus Native Transcatheter Aortic Valve Implantation.

Akodad M, Meilhac A, Lefèvre T, Cayla G, Lattuca B, Autissier C, Duflos C, Gandet T, Macia JC, Delseny D, Roubille F, Maupas E, Schmutz L, Piot C, Targosz F, Robert G, Rivalland F, Albat B, Chevalier B, Leclercq F.

Am J Cardiol. 2019 Jul 1;124(1):90-97. doi: 10.1016/j.amjcard.2019.04.009. Epub 2019 Apr 18.

PMID:
31076081
5.

Is sex associated with adverse outcomes after percutaneous coronary intervention for CTO?

Akodad M, Spaziano M, Garcia-Alonso CJ, Louvard Y, Sanguineti F, Garot P, Hovasse T, Unterseeh T, Chevalier B, Lefèvre T, Benamer H.

Int J Cardiol. 2019 Aug 1;288:29-33. doi: 10.1016/j.ijcard.2019.04.033. Epub 2019 Apr 11.

PMID:
31047703
6.

Comparison of long-term clinical outcomes in multivessel coronary artery disease patients treated either with bioresoarbable polymer sirolimus-eluting stent or permanent polymer everolimus-eluting stent: 5-year results of the CENTURY II randomized clinical trial.

Iñiguez A, Chevalier B, Richardt G, Neylon A, Jiménez VA, Kornowski R, Carrie D, Moreno R, Barbato E, Serra-Peñaranda A, Guiducci V, Valdés-Chávarri M, Yajima J, Wijns W, Saito S; CENTURY II study investigators.

Catheter Cardiovasc Interv. 2019 Apr 29. doi: 10.1002/ccd.28224. [Epub ahead of print]

PMID:
31033154
7.

Assessment of Long-Term Structural Deterioration of Transcatheter Aortic Bioprosthetic Valves Using the New European Definition.

Durand E, Sokoloff A, Urena-Alcazar M, Chevalier B, Chassaing S, Didier R, Tron C, Litzler PY, Bouleti C, Himbert D, Hovasse T, Bar O, Avinée G, Iung B, Blanchard D, Gilard M, Cribier A, Lefevre T, Eltchaninoff H.

Circ Cardiovasc Interv. 2019 Apr;12(4):e007597. doi: 10.1161/CIRCINTERVENTIONS.118.007597.

PMID:
30998397
8.

Mechanical performance and healing patterns of the novel sirolimus-eluting bioresorbable Fantom scaffold: 6-month and 9-month follow-up by optical coherence tomography in the FANTOM II study.

Simonsen JK, Holck EN, Carrié D, Frey N, Lutz M, Weber-Albers J, Dudek D, Chevalier B, Daemen J, Dijkstra J, Fox Maule C, Neghabat O, Lassen JF, Anderson J, Christiansen EH, Abizaid A, Holm NR.

Open Heart. 2019 Feb 28;6(1):e000941. doi: 10.1136/openhrt-2018-000941. eCollection 2019.

9.

Prognostic Impact of Pre-Transcatheter and Post-Transcatheter Aortic Valve Intervention Troponin: A Large Cohort Study.

Akodad M, Spaziano M, Chevalier B, Garot P, Benamer H, Dinan-Zannier A, Troussier X, Unterseeh T, Champagne S, Hovasse T, Lefèvre T.

J Am Heart Assoc. 2019 Mar 19;8(6):e011111. doi: 10.1161/JAHA.118.011111.

10.

Design and rationale of the Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated Versus Standard DAPT Regimen (MASTER DAPT) Study.

Frigoli E, Smits P, Vranckx P, Ozaki Y, Tijssen J, Jüni P, Morice MC, Onuma Y, Windecker S, Frenk A, Spaulding C, Chevalier B, Barbato E, Tonino P, Hildick-Smith D, Roffi M, Kornowski R, Schultz C, Lesiak M, Iñiguez A, Colombo A, Alasnag M, Mullasari A, James S, Stankovic G, Ong PJL, Rodriguez AE, Mahfoud F, Bartunek J, Moschovitis A, Laanmets P, Leonardi S, Heg D, Sunnåker M, Valgimigli M.

Am Heart J. 2019 Mar;209:97-105. doi: 10.1016/j.ahj.2018.10.009. Epub 2018 Nov 22.

11.

Implementation of the transradial approach as an alternative vascular access for transcatheter aortic valve replacement guidance: Experience from a high-volume center.

Fernandez-Lopez L, Chevalier B, Lefèvre T, Spaziano M, Unterseeh T, Champagne S, Benamer H, Sanguineti F, Garot P, Hovasse T.

Catheter Cardiovasc Interv. 2019 Jun 1;93(7):1367-1373. doi: 10.1002/ccd.28024. Epub 2018 Dec 10.

PMID:
30536569
12.

1-Year Outcomes With the Evolut R Self-Expanding Transcatheter Aortic Valve: From the International FORWARD Study.

Manoharan G, Van Mieghem NM, Windecker S, Bosmans J, Bleiziffer S, Modine T, Linke A, Scholtz W, Chevalier B, Gooley R, Zeng C, Oh JK, Grube E.

JACC Cardiovasc Interv. 2018 Nov 26;11(22):2326-2334. doi: 10.1016/j.jcin.2018.07.032.

PMID:
30466832
13.

Transcatheter Aortic Valve Replacement in the Catheterization Laboratory Versus Hybrid Operating Room: Insights From the FRANCE TAVI Registry.

Spaziano M, Lefèvre T, Romano M, Eltchaninoff H, Leprince P, Motreff P, Iung B, Van Belle E, Koning R, Verhoye JP, Gilard M, Garot P, Hovasse T, Le Breton H, Chevalier B.

JACC Cardiovasc Interv. 2018 Nov 12;11(21):2195-2203. doi: 10.1016/j.jcin.2018.06.043.

PMID:
30409276
14.

Hydrogen Insertion in the Intermetallic GdScGe: A Drastic Reduction of the Dimensionality of the Magnetic and Transport Properties.

Mahon T, Gaudin E, Villesuzanne A, Decourt R, Bobet JL, Isnard O, Chevalier B, Tencé S.

Inorg Chem. 2018 Nov 19;57(22):14230-14239. doi: 10.1021/acs.inorgchem.8b02247. Epub 2018 Nov 8.

PMID:
30407001
15.

Position paper of French Interventional Group (GACI) for TAVI in France in 2018.

Benamer H, Auffret V, Cayla G, Chevalier B, Dupouy P, Eltchaninoff H, Gilard M, Guerin P, Iung B, Koning R, Monsegu J, Lantelme P, Le Breton H, Lefèvre T, Verhoye JP, Commeau P, Motreff P.

Ann Cardiol Angeiol (Paris). 2018 Dec;67(6):455-465. doi: 10.1016/j.ancard.2018.09.021. Epub 2018 Oct 28.

PMID:
30376969
16.

Polymer-free drug-coated stents: workhorse or "niche horse"?

Urban P, Chevalier B.

EuroIntervention. 2018 Sep 20;14(7):732-735. doi: 10.4244/EIJV14I7A128. No abstract available.

17.

The "one airway, one disease" concept in light of Th2 inflammation.

Giovannini-Chami L, Paquet A, Sanfiorenzo C, Pons N, Cazareth J, Magnone V, Lebrigand K, Chevalier B, Vallauri A, Julia V, Marquette CH, Marcet B, Leroy S, Barbry P.

Eur Respir J. 2018 Oct 25;52(4). pii: 1800437. doi: 10.1183/13993003.00437-2018. Print 2018 Oct.

PMID:
30190271
18.

Angiographic late lumen loss revisited: impact on long-term target lesion revascularization.

Asano T, Serruys PW, Collet C, Miyazaki Y, Takahashi K, Chichareon P, Katagiri Y, Modolo R, Tenekecioglu E, Morel MA, Garg S, Wykrzykowska J, Piek JJ, Sabate M, Morice MC, Chevalier B, Windecker S, Onuma Y.

Eur Heart J. 2018 Sep 21;39(36):3381-3389. doi: 10.1093/eurheartj/ehy436.

PMID:
30124834
19.

Left Main Bifurcation Angioplasty: Are 2 Stents One Too Many?

Chevalier B.

JACC Cardiovasc Interv. 2018 Jul 9;11(13):1259-1261. doi: 10.1016/j.jcin.2018.04.015. No abstract available.

20.

Acute and Long-term Relocation of Minimal Lumen Area after Bioresorbable Scaffold or Metallic Stent Implantation.

Katagiri Y, Serruys PW, Tenekecioglu E, Asano T, Collet C, Miyazaki Y, Katsikis A, Piek JJ, Wykrzykowska JJ, Chevalier B, Mintz GS, Stone GW, Onuma Y.

EuroIntervention. 2018 Jul 3. pii: EIJ-D-18-00422. doi: 10.4244/EIJ-D-18-00422. [Epub ahead of print]

21.

The Long-Term Impact of Post-Procedural Asymmetry and Eccentricity of Bioresorbable Everolimus-Eluting Scaffold and Metallic Everolimus-Eluting Stent on Clinical Outcomes in the ABSORB II Trial.

Katagiri Y, Serruys PW, Macaya C, Ormiston JA, Hill J, Lang IM, Egred M, Fajadet J, Lesiak M, Wykrzykowska JJ, Piek JJ, Sabaté M, Windecker S, Chevalier B, Onuma Y.

JACC Cardiovasc Interv. 2018 May 28;11(10):1013-1015. doi: 10.1016/j.jcin.2018.02.020. No abstract available.

22.

Using Discursis to enhance the qualitative analysis of hospital pharmacist-patient interactions.

Chevalier BAM, Watson BM, Barras MA, Cottrell WN, Angus DJ.

PLoS One. 2018 May 22;13(5):e0197288. doi: 10.1371/journal.pone.0197288. eCollection 2018.

23.

Relation between bioresorbable scaffold sizing using QCA-Dmax and long-term clinical outcomes in 1,232 patients from three study cohorts (ABSORB Cohort B, ABSORB EXTEND, and ABSORB II).

Katagiri Y, Onuma Y, Asano T, Chichareon P, Collet C, Miyazaki Y, Piek JJ, Wykrzykowska JJ, Abizaid A, Ormiston JA, Chevalier B, Serruys PW.

EuroIntervention. 2018 Oct 12;14(9):e1057-e1066. doi: 10.4244/EIJ-D-18-00301.

24.

Factors influencing readthrough therapy for frequent cystic fibrosis premature termination codons.

Pranke I, Bidou L, Martin N, Blanchet S, Hatton A, Karri S, Cornu D, Costes B, Chevalier B, Tondelier D, Girodon E, Coupet M, Edelman A, Fanen P, Namy O, Sermet-Gaudelus I, Hinzpeter A.

ERJ Open Res. 2018 Feb 23;4(1). pii: 00080-2017. doi: 10.1183/23120541.00080-2017. eCollection 2018 Jan. Erratum in: ERJ Open Res. 2018 Jul 13;4(3):.

25.

Cis variants identified in F508del complex alleles modulate CFTR channel rescue by small molecules.

Baatallah N, Bitam S, Martin N, Servel N, Costes B, Mekki C, Chevalier B, Pranke I, Simonin J, Girodon E, Hoffmann B, Mornon JP, Callebaut I, Sermet-Gaudelus I, Fanen P, Edelman A, Hinzpeter A.

Hum Mutat. 2018 Apr;39(4):506-514. doi: 10.1002/humu.23389. Epub 2018 Jan 16.

PMID:
29271547
26.

Serial Assessment of Strut Coverage of Biodegradable Polymer Drug-Eluting Stent at 1, 2, and 3 Months After Stent Implantation by Optical Frequency Domain Imaging: The DISCOVERY 1TO3 Study (Evaluation With OFDI of Strut Coverage of Terumo New Drug Eluting Stent With Biodegradable Polymer at 1, 2, and 3 Months).

Chevalier B, Smits PC, Carrié D, Mehilli J, Van Boven AJ, Regar E, Sawaya FJ, Chamié D, Kraaijeveld AO, Hovasse T, Vlachojannis GJ.

Circ Cardiovasc Interv. 2017 Dec;10(12). pii: e004801. doi: 10.1161/CIRCINTERVENTIONS.116.004801.

27.

Hospital pharmacists' and patients' views about what constitutes effective communication between pharmacists and patients.

Chevalier BAM, Watson BM, Barras MA, Cottrell WN.

Int J Pharm Pract. 2018 Oct;26(5):450-457. doi: 10.1111/ijpp.12423. Epub 2017 Dec 6.

PMID:
29210472
28.

Effect of Technique on Outcomes Following Bioresorbable Vascular Scaffold Implantation: Analysis From the ABSORB Trials.

Stone GW, Abizaid A, Onuma Y, Seth A, Gao R, Ormiston J, Kimura T, Chevalier B, Ben-Yehuda O, Dressler O, McAndrew T, Ellis SG, Kereiakes DJ, Serruys PW.

J Am Coll Cardiol. 2017 Dec 12;70(23):2863-2874. doi: 10.1016/j.jacc.2017.09.1106. Epub 2017 Oct 31.

29.

Four-year follow-up of the randomised comparison between an everolimus-eluting bioresorbable scaffold and an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II Trial).

Chevalier B, Cequier A, Dudek D, Haude M, Carrie D, Sabaté M, Windecker S, Reith S, de Sousa Almeida M, Campo G, Iñiguez A, Onuma Y, Serruys PW.

EuroIntervention. 2018 Jan 20;13(13):1561-1564. doi: 10.4244/EIJ-D-17-00873. No abstract available.

30.

Three-Year Outcomes With the Absorb Bioresorbable Scaffold: Individual-Patient-Data Meta-Analysis From the ABSORB Randomized Trials.

Ali ZA, Gao R, Kimura T, Onuma Y, Kereiakes DJ, Ellis SG, Chevalier B, Vu MT, Zhang Z, Simonton CA, Serruys PW, Stone GW.

Circulation. 2018 Jan 30;137(5):464-479. doi: 10.1161/CIRCULATIONAHA.117.031843. Epub 2017 Oct 31.

PMID:
29089314
31.

Polymers and coronary stents: have we come full circle?

Urban P, Chevalier B.

Cardiovasc Revasc Med. 2017 Oct - Nov;18(7):471-472. doi: 10.1016/j.carrev.2017.09.007. No abstract available.

PMID:
29054155
32.

Simultaneous TAVR and Left Main "Chimney" Stenting in a Patient With Low Left Main Height.

Spaziano M, Akodad M, Hovasse T, Lefèvre T, Bouvier E, Chevalier B.

JACC Cardiovasc Interv. 2017 Oct 23;10(20):e185-e187. doi: 10.1016/j.jcin.2017.06.047. Epub 2017 Sep 27. No abstract available.

33.

6-Month Clinical and Angiographic Outcomes of a Novel Radiopaque Sirolimus-Eluting Bioresorbable Vascular Scaffold: The FANTOM II Study.

Abizaid A, Carrié D, Frey N, Lutz M, Weber-Albers J, Dudek D, Chevalier B, Weng SC, Costa RA, Anderson J, Stone GW; FANTOM II Clinical Investigators.

JACC Cardiovasc Interv. 2017 Sep 25;10(18):1832-1838. doi: 10.1016/j.jcin.2017.07.033.

34.

Diagnostic Accuracy of Coronary CT Angiography for the Evaluation of Bioresorbable Vascular Scaffolds.

Collet C, Chevalier B, Cequier A, Fajadet J, Dominici M, Helqvist S, Van Boven AJ, Dudek D, McClean D, Almeida M, Piek JJ, Tenekecioglu E, Bartorelli A, Windecker S, Serruys PW, Onuma Y.

JACC Cardiovasc Imaging. 2018 May;11(5):722-732. doi: 10.1016/j.jcmg.2017.04.013. Epub 2017 Jul 19.

PMID:
28734923
35.

Arterial Remodeling After Bioresorbable Scaffolds and Metallic Stents.

Serruys PW, Katagiri Y, Sotomi Y, Zeng Y, Chevalier B, van der Schaaf RJ, Baumbach A, Smits P, van Mieghem NM, Bartorelli A, Barragan P, Gershlick A, Kornowski R, Macaya C, Ormiston J, Hill J, Lang IM, Egred M, Fajadet J, Lesiak M, Windecker S, Byrne RA, Räber L, van Geuns RJ, Mintz GS, Onuma Y.

J Am Coll Cardiol. 2017 Jul 4;70(1):60-74. doi: 10.1016/j.jacc.2017.05.028.

36.

Investigating strategies used by hospital pharmacists to effectively communicate with patients during medication counselling.

Chevalier BAM, Watson BM, Barras MA, Cottrell WN.

Health Expect. 2017 Oct;20(5):1121-1132. doi: 10.1111/hex.12558. Epub 2017 Mar 30.

37.

Outcomes in Transcatheter Aortic Valve Replacement for Bicuspid Versus Tricuspid Aortic Valve Stenosis.

Yoon SH, Bleiziffer S, De Backer O, Delgado V, Arai T, Ziegelmueller J, Barbanti M, Sharma R, Perlman GY, Khalique OK, Holy EW, Saraf S, Deuschl F, Fujita B, Ruile P, Neumann FJ, Pache G, Takahashi M, Kaneko H, Schmidt T, Ohno Y, Schofer N, Kong WKF, Tay E, Sugiyama D, Kawamori H, Maeno Y, Abramowitz Y, Chakravarty T, Nakamura M, Kuwata S, Yong G, Kao HL, Lee M, Kim HS, Modine T, Wong SC, Bedgoni F, Testa L, Teiger E, Butter C, Ensminger SM, Schaefer U, Dvir D, Blanke P, Leipsic J, Nietlispach F, Abdel-Wahab M, Chevalier B, Tamburino C, Hildick-Smith D, Whisenant BK, Park SJ, Colombo A, Latib A, Kodali SK, Bax JJ, Søndergaard L, Webb JG, Lefèvre T, Leon MB, Makkar R.

J Am Coll Cardiol. 2017 May 30;69(21):2579-2589. doi: 10.1016/j.jacc.2017.03.017. Epub 2017 Mar 18.

38.

Long-term serial non-invasive multislice computed tomography angiography with functional evaluation after coronary implantation of a bioresorbable everolimus-eluting scaffold: the ABSORB cohort B MSCT substudy.

Onuma Y, Collet C, van Geuns RJ, de Bruyne B, Christiansen E, Koolen J, Smits P, Chevalier B, McClean D, Dudek D, Windecker S, Meredith I, Nieman K, Veldhof S, Ormiston J, Serruys PW; ABSORB Investigators.

Eur Heart J Cardiovasc Imaging. 2017 May 1;18(8):870-879. doi: 10.1093/ehjci/jex022.

PMID:
28329198
39.

Does geographical variability influence five-year MACCE rates in the multicentre SYNTAX revascularisation trial?

Roy AK, Chevalier B, Lefèvre T, Louvard Y, Segurado R, Sawaya F, Spaziano M, Neylon A, Serruys PA, Dawkins KD, Kappetein AP, Mohr FW, Colombo A, Feldman T, Morice MC.

EuroIntervention. 2017 Sep 20;13(7):828-834. doi: 10.4244/EIJ-D-16-00991.

40.

Novel integrated 3D multidetector computed tomography and fluoroscopy fusion for left atrial appendage occlusion procedures.

Roy AK, Horvilleur J, Cormier B, Cazalas M, Fernandez L, Patane M, Neylon A, Spaziano M, Sawaya FJ, Arai T, Bouvier E, Hovasse T, Lefèvre T, Chevalier B, Garot P.

Catheter Cardiovasc Interv. 2018 Feb 1;91(2):322-329. doi: 10.1002/ccd.26998. Epub 2017 Mar 17.

PMID:
28303634
41.

Incidence and predictors of coronary obstruction following transcatheter aortic valve implantation in the real world.

Arai T, Lefèvre T, Hovasse T, Garot P, Benamer H, Unterseeh T, Roy AK, Romano M, Hayashida K, Watanabe Y, Bouvier E, Morice MC, Chevalier B.

Catheter Cardiovasc Interv. 2017 Dec 1;90(7):1192-1197. doi: 10.1002/ccd.26982. Epub 2017 Mar 15.

PMID:
28295996
42.

The feasibility of transcatheter aortic valve implantation using the Edwards SAPIEN 3 for patients with severe bicuspid aortic stenosis.

Arai T, Lefèvre T, Hovasse T, Morice MC, Romano M, Benamer H, Garot P, Hayashida K, Bouvier E, Chevalier B.

J Cardiol. 2017 Sep;70(3):220-224. doi: 10.1016/j.jjcc.2016.12.009. Epub 2017 Feb 10.

43.

Characterizing isomiR variants within the microRNA-34/449 family.

Mercey O, Popa A, Cavard A, Paquet A, Chevalier B, Pons N, Magnone V, Zangari J, Brest P, Zaragosi LE, Ponzio G, Lebrigand K, Barbry P, Marcet B.

FEBS Lett. 2017 Mar;591(5):693-705. doi: 10.1002/1873-3468.12595. Epub 2017 Feb 28.

44.

Health Care Professionals' Opinions and Expectations of Clinical Pharmacy Services on a Surgical Ward.

Chevalier B, Neville HL, Thompson K, Nodwell L, MacNeil M.

Can J Hosp Pharm. 2016 Nov-Dec;69(6):439-448. Epub 2016 Dec 23.

45.

Comparison between the SAPIEN S3 and the SAPIEN XT transcatheter heart valves: A single-center experience.

Sawaya FJ, Spaziano M, Lefèvre T, Roy A, Garot P, Hovasse T, Neylon A, Benamer H, Romano M, Unterseeh T, Morice MC, Chevalier B.

World J Cardiol. 2016 Dec 26;8(12):735-745. doi: 10.4330/wjc.v8.i12.735.

46.

Comparison of Systematic Predilation, Selective Predilation, and Direct Transcatheter Aortic Valve Implantation With the SAPIEN S3 Valve.

Spaziano M, Sawaya F, Chevalier B, Roy A, Neylon A, Garot P, Hovasse T, Benamer H, Romano M, Unterseeh T, Bouvier E, Cormier B, Morice MC, Lefèvre T.

Can J Cardiol. 2017 Feb;33(2):260-268. doi: 10.1016/j.cjca.2016.09.007. Epub 2016 Oct 4.

PMID:
28034581
47.

Efficacy and Safety of the Absorb Everolimus-Eluting Bioresorbable Scaffold for Treatment of Patients With Diabetes Mellitus: Results of the Absorb Diabetic Substudy.

Kereiakes DJ, Ellis SG, Kimura T, Abizaid A, Zhao W, Veldhof S, Vu MT, Zhang Z, Onuma Y, Chevalier B, Serruys PW, Stone GW.

JACC Cardiovasc Interv. 2017 Jan 9;10(1):42-49. doi: 10.1016/j.jcin.2016.10.019. Epub 2016 Dec 21.

48.

Comparative assessment of "plaque/media" change on three modalities of IVUS immediately after implantation of either everolimus-eluting bioresorbable vascular scaffold or everolimus-eluting metallic stent in Absorb II study.

Zeng Y, Cavalcante R, Tenekecioglu E, Suwannasom P, Sotomi Y, Collet C, Abdelghani M, Jonker H, Digne F, Horstkotte D, Zehender M, Indolfi C, Saia F, Fiorilli R, Chevalier B, Bolognese L, Goicolea J, Nie S, Onuma Y, Serruys PW; investigators of Absorb II study.

Int J Cardiovasc Imaging. 2017 Apr;33(4):441-449. doi: 10.1007/s10554-016-1033-7. Epub 2016 Dec 23.

49.

Chronic total coronary occlusion treated by percutaneous coronary intervention: long-term outcome in patients with and without diabetes.

Sanguineti F, Garot P, O'Connor S, Watanabe Y, Spaziano M, Lefèvre T, Hovasse T, Benamer H, Unterseeh T, Chevalier B, Morice MC, Louvard Y.

EuroIntervention. 2017 Feb 3;12(15):e1889-e1897. doi: 10.4244/EIJ-D-15-00278.

50.

Direct Comparison of Feasibility and Safety of Transfemoral Versus Transaortic Versus Transapical Transcatheter Aortic Valve Replacement.

Arai T, Romano M, Lefèvre T, Hovasse T, Farge A, Le Houerou D, Hayashida K, Watanabe Y, Garot P, Benamer H, Unterseeh T, Bouvier E, Morice MC, Chevalier B.

JACC Cardiovasc Interv. 2016 Nov 28;9(22):2320-2325. doi: 10.1016/j.jcin.2016.08.009.

Supplemental Content

Loading ...
Support Center